ArticleAmerican journal of translational research2026
Effects of intravenous dexmedetomidine on hemodynamic stability, inflammatory factors, and brain injury biomarkers in patients with Moyamoya disease undergoing revascularization surgery.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Effect of Dexmedetomidine on Postoperative Acute Kidney Injury in High-Risk Partial Nephrectomy Patients: A Retrospective Cohort Study.Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the effects of dexmedetomidine (DEX) on perioperative hemodynamic stability, inflammatory response, and brain injury markers in patients with moyamoya disease (MMD) undergoing revascularization procedures.
methodsA total of 68 patients with confirmed MMD were enrolled in this single-institution, randomized, placebo-controlled, prospective trial and were randomized into either the DEX group or the placebo group (34 patients each). The DEX group received a loading dose of 1 µg/kg DEX and a continuous infusion at 0.4 µg/kg/h throughout the surgery. Instead, the control group was given the same volume of saline with the same dosing regimen. Hemodynamic parameters, including heart rate (HR), systolic blood pressure (SBP), mean blood pressure (MAP), and diastolic blood pressure (DBP), were recorded at six defined time points: before induction (T0), during tracheal intubation (T1), at the moment of surgical incision (T2), immediately after surgery (T3), before extubation (T4), and during extubation (T5). Additionally, fluctuation amplitudes for heart rate variability (HR-V), systolic blood pressure variability (SBP-V), and mean arterial pressure variability (MAP-V) were calculated from data collected during T0-T5. Plasma levels of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), the neural injury marker S100 beta protein (S100β) and neuron-specific enolase (NSE) were obtained at four different time points: prior to anesthesia induction, after reperfusion, immediately after surgery, and 24 hours postoperatively. Adverse events and neurological complications within 24 hours postoperatively were also documented.
resultsCompared with control group, DEX group exhibited significantly lower SBP, MAP, and DBP at time points T1, T2, T4, and T5 (all
conclusionsIntraoperative infusion of DEX enhances perioperative hemodynamic stability, mitigated postoperative inflammatory response, and lowers serum S100β levels associated with brain injury in MMD patients undergoing superficial temporal artery-middle cerebral artery (STA-MCA) bypass surgery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.